Furthermore, alectinib showed more favorable PFS and adverse event profiles than crizotinib in a phase 3 head-to-head comparison trial in Japanese patients with ALK-inhibitor-naïve ALK+ NSCLC [11]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.